Antiretroviral treatment

The European Commission has granted marketing authorization for Epclusa ( Sofosbuvir 400 mg / Velpatasvir 100 mg ), the first...


Delamanid ( Deltyba ), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis ( TB ) drug which exhibits potent in vitro...


The FDA ( Food and Drug Administration ) has approved Genvoya ( a fixed-dose combination tablet containing Elvitegravir, Cobicistat, Emtricitabine,...


The FDA ( Food and Drug Administration ) has approved Genvoya ( Elvitegravir 150 mg / Cobicistat 150 mg /...


Six treatment options are available in 2015 for patients infected with HCV genotype 1, including two IFN-containing regimens and four...


Results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 ( HIV-1 ) co-infection ( TURQUOISE-I...


The optimum dose of key antiretroviral drugs is often overlooked during product development. The ENCORE1 study compared the efficacy and...


Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. However,...


Present combination antiretroviral therapy ( cART ) alone does not cure HIV infection and requires lifelong drug treatment. The potential...


Health Canada has received a published case report of a potential drug-herb interaction between Efavirenz ( Sustiva ) and a...


CCR5 is the major coreceptor for human immunodeficiency virus ( HIV ). Researchers have investigated whether site-specific modification of the...


Uncertainty exists about the best treatment for people with HIV-1 who have virological failure with first-line combination antiretroviral therapy of...


Short-course antiretroviral therapy ( ART ) in primary human immunodeficiency virus ( HIV ) infection may delay disease progression but...


In the primary analysis of SPRING-2 at week 48, Dolutegravir ( Tivicay ) has shown non-inferior efficacy to and similar...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to...


Dolutegravir ( Tivicay ), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. Researchers...


Gilead Sciences has announced results from a phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue Sofosbuvir for the...


Gilead Sciences has announced that the Antiviral Drugs Advisory Committee of the FDA ( Food and Drug Administration ) has...


In the absence of antiretroviral therapy ( ART ), over 50% of HIV-infected infants progress to AIDS and death by...